StockNews.com Begins Coverage on TRACON Pharmaceuticals (NASDAQ:TCON)

StockNews.com assumed coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research report report published on Friday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a neutral rating on shares of TRACON Pharmaceuticals in a research report on Monday, July 1st.

TRACON Pharmaceuticals Stock Performance

Shares of TCON opened at $0.13 on Friday. The firm has a market capitalization of $453,189.00, a price-to-earnings ratio of 0.20 and a beta of 1.36. TRACON Pharmaceuticals has a one year low of $0.00 and a one year high of $14.75. The stock’s fifty day moving average is $0.14 and its 200-day moving average is $1.51.

TRACON Pharmaceuticals (NASDAQ:TCON) last announced its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) EPS for the quarter. The business had revenue of $0.06 million during the quarter.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.